FDA allows fruit-flavored e-cigarettes May 22

The Food and Drug Administration took two separate steps this month that together changed the U.S. vaping market. On May 8, the agency issued enforcement guidance saying it does not intend to prioritize action against certain unauthorized e-cigarette and nicotine pouch products while their applications are under review. Around the same time, the FDA also authorized new flavored e-cigarettes and said non-tobacco flavors can meet the public-health standard if companies show youth access can be effectively restricted. Democratic senators have asked the agency to reverse course, arguing the move risks reviving youth vaping. ### What exactly did the FDA change? The FDA said on May 8 that its new guidance covers “certain new tobacco products marketed without premarket authorization,” including e-cigarettes and nicotine pouch products. The agency said the policy describes when it does not intend to prioritize enforcement against unauthorized products, rather than granting blanket legality. A separate FDA press release said the agency had authorized additional electronic nicotine delivery system products and described device-based age-gating as “an additional way” for a non-tobacco flavored product to satisfy the legal standard. The agency said the reviewed device required government-ID verification, smartphone pairing and random biometric check-ins. (fda.gov) ### Did the FDA really authorize fruit flavors? Sen. Dick Durbin’s office said on May 20 that the FDA had authorized “the first-ever non-tobacco or menthol-flavored vaping products” and identified blueberry and mango flavors in his letter to Health and Human Services Secretary Robert F. Kennedy Jr. (fda.gov) The FDA’s own materials say non-tobacco flavored products may be authorized if an application shows benefits for adults who smoke outweigh risks of youth initiation, and if youth access is effectively limited. The agency’s authorized e-cigarette page says newly authorized products are added there first and then to its searchable tobacco-products database. ### Why are senators objecting? (durbin.senate.gov) Senators Richard Blumenthal of Connecticut and Jeff Merkley of Oregon led a group of 10 Democrats in a May 18 letter to Acting FDA Commissioner Kyle Diamantas asking him to rescind the flavored-product authorization. They wrote that “there is no scientific consensus” that flavors help adults quit tobacco, while “clear data” show flavored products attract young people. (fda.gov) The same letter cited the 2025 National Youth Tobacco Survey and said more than 1.4 million middle and high school students still use e-cigarettes. The senators also said FDA figures show nearly all youth who use e-cigarettes use flavored products, with fruit flavors the most popular. ### What is the FDA’s argument for allowing them? (merkley.senate.gov) Bret Koplow, acting director of the FDA’s Center for Tobacco Products, said device access restrictions are “a potential game changer” because they could help prevent youth use while allowing “an expanded array of flavored options” for adults who smoke and may switch completely from cigarettes. The FDA’s March 2026 draft guidance on flavored electronic nicotine delivery systems did not itself authorize products, but it said the document was intended to help companies prepare premarket applications and described the agency’s current thinking on youth-risk issues. (merkley.senate.gov) The guidance is non-binding and remains open to future revision or rulemaking. (fda.gov) ### What should readers watch next? The FDA’s searchable tobacco-products database and its authorized e-cigarette page are the agency’s main public records for products that may be legally marketed in the United States. The nicotine pouch authorization page separately lists pouch products the agency says may lawfully be sold. (fda.gov) Congressional pressure is also continuing. Durbin has already asked Kennedy to intervene, and the Blumenthal-Merkley group has asked Diamantas to rescind the flavored authorizations immediately. Any formal reversal, new authorization, or enforcement update would be expected to appear first in FDA postings or Senate offices’ public releases. (merkley.senate.gov) (fda.gov)